La Montagne R

Motte, Warren; Jouet, Jacques

doi:10.2307/40042126

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD86 expression in a vaccinia delivery system leads to protective tumor immunity (14). Other reports demonstrate the tumor model specificity of the CD86-mediated immunity (15,16). In one study, expression of CD86 was clearly superior to that of CD80 in adenocarcinoma and melanoma systems (17).…”

Section: Discussionmentioning

confidence: 98%

“…Less clear is the role of CD86 expression in tumor immunity. Some reports have suggested CD86 expression is not effective in generating tumor immunity (9-13); however, several tumor model systems do derive great benefit from CD86 expression (14)(15)(16)(17). In the case of both CD80 and CD86, expression of these costimulatory molecules in the absence of MHC protein expression would be expected to be ineffective.…”

Section: Malignant Cells Utilize Many Different Mechanisms To Evade Tmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of MHC Class II Transactivator on the Growth and Metastasis of Breast Tumors

Martin¹,

Ting²

1999

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. I have continued my investigations into the effect of the MHC class II transactivator, CIITA, on the growth and immunogenicity in breast cancer. I have utilized three different model sytems; MT901,4T1 and EMT6. In the MT901 cell line, CIITA expression does not change in vivo tumor growth properties. In the 4T1 model, expression of CIITA leads to direct killing of the tumor in vitro, suggesting that CIITA has a toxic effect in this cell line. We are actively investigating inducible CIITA expression systems to fully investigate this phenomenon. We have also investigated immunogenicity of CIITA expressing tumors. MT901 is immunogenic and cannot be used in these assays, therefore we have used the Line 1 lung carcinoma as a surrogate system (we have also started to examine EMT6 as an additional mammary tumor model). We have found that CIITA expression can result in more mice with tumor formation, suggesting a negative role for CIITA in the absence of costimulation. We have initiated preliminary investigations into novel genes induced by CIITA. The results of these experiments have important implications in proposed CIITA-human gene therapy trials.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Malignant Cells Utilize Many Different Mechanisms To Evade Tmentioning

confidence: 99%